On behalf of the entire Bioceltix team, we would like to wish you a very successful, healthy and joyful New Year. We look forward to our work ...
Read fullMamStartup: Bioceltix is a biotech startup that does business in the veterinary industry – the company focuses on developing ...
Read fullWe hope you had a chance to tune in to „Radio dla Ciebie” during the „Let’s start with Innovation” („Innowacje na start”) show – that’s for ...
Read full
Another round of the prestigious contest designed for social-involved startups – Chivas Venture– is behind us. We are among the five ...
Read fullThe CEO of Bioceltix, Łukasz Bzdion, during an interview for Channel 4 of Polish Radio, answered question regarding the possibility of treating ...
Read fullThe jury has spoken… and unveiled their list of finalists in the forth edition of Chivas Venture contest designed for startups that are socially ...
Read fullbiotechnologia.pl: Poland is among the countries where innovative biopharmaceuticals re being designed to treat household animals. Bioceltix is ...
Read full
We are one of 18 innovative companies taking part in the 5th edition of MIT Enterprise Forum Poland accelerator program. There are three months ...
Read fullproseedmag: the MIT Enterprise Forum Poland program aims to speed up the development of recently-established tech companies. It accomplishes this ...
Read fullMIT Enterprise Forum Poland, one of the largest accelerator programs in Poland, is part of the MIT Enterprise Forum network. The program, which ...
Read fullAll of the stem-cell-based biopharmaceuticals being developed by our company are designed to treat conditions caused by chronic inflammatory ...
Read full
All hands on deck! Our research and development center is hard at work! Karol Wrzeszcz, our quality control expert, is supervising the job and ...
Read full
The 2nd phase of MIT Enterprise Forum Poland took place at Adamed headquarters on Friday (24 August). During the meeting Paweł Wielgus, a member ...
Read fullThe gala that concluded the 8th edition of this ranking took place on June 27th at Warsaw’s Multikino Złote Tarasy. This time the event was ...
Read fullOn Friday, August 24th, as part of our involvement in the accelerator program organized by MIT Poland, we are participating in a meeting during ...
Read fullGazeta Wrocławska: Bioceltix develops biological drugs for common pet diseases. At the moment, the company is working on drugs for locomotor ...
Read fullScientists, experts and entrepreneurs from Wroclaw have been recognized in the Most Creative Minds in Business Ranking published by Brief ...
Read fullWrocław scientists in the comfort of laboratories are preparing drugs that change the standards of treating dogs, cats and horses. Just a little ...
Read full
The Jury of the 8th edition of The 50 Most Creative in Business ranking has decided – Łukasz Bzdzion, Bioceltix CEO, took the second place. The ...
Read fullAs the first company in Europe, Bioceltix intends to authorize a veterinary biopharmaceutical based on stem cells. Łukasz Bzdzion, the CEO of the ...
Read fullWe was on Impact’18, congress that brings leaders at the forefront of innovation from many sectors together to explore the opportunities ...
Read fullCEO of Bioceltix, Łukasz Bzdzion, during the WallStreet conference in Karpacz talked about the AlloMSCs technology, biopharmaceuticals based on ...
Read fullRanking The 50 Most Creative in Business is an initiative that for 7 years has been helping to build and promote the innovative and creative ...
Read full– We are the first company in Europe to develop and implement animal-safe and business-scale technology that uses allogeneic stem cells in ...
Read fullTo 2020, the participation of biological medicines in the entire pharmaceutical market will increase to nearly 30%. The veterinary market will ...
Read fullFounder and President of Bioceltix is of two natures – the one of an experienced scientist and the one of an entrepreneur, subjecting medical ...
Read fullBetween May 25 and 27, the largest Poland-based meeting in of individual investors with entities related to the capital market in Eastern Europe ...
Read full
At the beginning of May, specialists from Bioceltix – jointly with engineers from the Czech-based Block company – conducted functional tests ...
Read fullA stem-cell therapy carried out in the allogeneic setting, standing for one donor-many recipients, enables the manufacture of a batch of the ...
Read fullOne of last year’s beneficiaries of Sub-measure 1.1.1 of the Intelligent Development Operational Program 2014-2020 is Bioceltix, a Wroclaw ...
Read full
Our production and quality control facilities are being upgraded to cGMP standards. More equipment designed for quality control of stem ...
Read full
We have concluded a contract with the Czech company BLOCK for a cGMP-compliant modular cell production system for clinical applications, to be ...
Read full
Bioceltix staff visited Spain for almost a week in order to finalise an equipment order for our laboratory. During these few days, we explored ...
Read fullThe Bioceltix team is developing its technology, upgrading its workspace to GMP standards and expanding its team. Our specialists were joined by ...
Read fullBioceltix has selected a supplier of isolated production line equipment. The contract has been awarded to the Czech company – BLOCK. The tender ...
Read fullOur Research and Development Centre and the cGMP-compliant manufacturing facility are located at EIT+, which is one of the most comprehensive ...
Read full
We wouldn’t dare miss the annual “Gospodarcze Otwarcie Roku” (Business Opening of the Year) conference on 21 February 2018. The meeting allows ...
Read fullWe are a team is dedicated to the constant search for new biotechnology solutions. We create top-of-the-line stem cell-based pharmaceuticals for ...
Read fullBioceltix is implementing the project entitled “The production of adipose tissue-derived allogeneic mesenchymal stem cells as compliant with the ...
Read fullBioceltix is implementing the project entitled “The production of adipose tissue-derived allogeneic mesenchymal stem cells as compliant with the ...
Read fullPuls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...
ArticleForbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...
ArticleAccording to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...
ArticleGazeta Wrocławska wrote about us: “Bioceltix is working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...
ArticleWe create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...
Article
